Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Pablo García‐Pavía, Mathew S. Maurer, Martin Carlsson et al.|Journal of Cardiac Failure|2024Cited by 45
Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection FractionBrian Drachman, Pablo García‐Pavía, Thibaud Damy et al.|European Journal of Heart Failure|2024Cited by 11
Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey PC149 (#8)Pablo García‐Pavía, Mat Maurer, V. Arnt et al.|Unknown|2024Cited by 1
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers populationMaría G. Crespo‐Leiro, Brian Drachman, Pablo García‐Pavía et al.|European Heart Journal|2024Cited by 0